Journal
AMERICAN JOURNAL OF CARDIOLOGY
Volume 103, Issue 7, Pages 1032-1038Publisher
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2008.12.014
Keywords
-
Categories
Funding
- Swedish Research Council. Stockholm, Sweden [K2003-71X-00676-21A]
- The Linne Foundation for Medical Research, Uppsala, Sweden
- AstraZeneca, Molndal, Sweden
Ask authors/readers for more resources
The aim of the present study was to evaluate whether B-type natriuretic peptides (BNPs) could serve as screening markers for the detection of preclinical vascular disease in the community. BNP and N-terminal-pro-BNP were analyzed in 1,000 subjects aged 70 years participating in the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study and were related to different measures of endothelial function and activation; arterial compliance, carotid atherosclerosis, and echocardiographic findings. The median levels were 42.0 ng/L for BNP and 110.7 ng/L for N-terminal-pro-BNP. On adjusted multivariate analysis, the 2 BNPs; were related to increased left ventricular mass and impaired left ventricular systolic and diastolic function but not to any of the other assessed entities reflecting preclinical vascular disease. In conclusion, BNPs are strong markers of increased left ventricular mass and impaired cardiac performance but cannot be regarded as useful screening markers for the detection of preclinical states of vascular disease in elderly subjects. (C) 2009 Published by Elsevier Inc. (Am J Cardiol 2009;103:1032-1038)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available